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Deficient activity of glucose-6-phosphatase (G6Pase) causes glycogen
storage disease type Ia (GSD Ia). We analysed the G6Pase gene of 16 GSD
Ia patients using single strand conformation polymorphism (SSCP) analysis
prior to automated sequencing of exon(s) revealing an aberrant SSCP pattern.
In all GSD Ia patients we were able to identify mutations on both alleles of
the G6Pase gene, indicating that this method is a reliable procedure to identify
mutations. Four novel mutations (175delGG, R170X, G266V and V338F)
were identified.
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Introduction
Glycogen storage disease type Ia (GSD Ia, McKusick 232200) which has
a frequency among new-borns of 1 in 100.000 to 1 in 300.000, is caused by
deficient glucose-6-phosphatase activity (G6Pase, E.C.3.1.3.9), the key
enzyme in homeostatic regulation of blood glucose concentration by catalysing
the terminal step in both glycogenolysis and gluconeogenesis. Severe fasting
hypoglycaemia is the most striking feature of this autosomal recessive inborn
error of metabolism. Other features are hyperlactacidaemia, hyperuricaemia,
hyperlipidaemia, a protruded abdomen due to marked hepatomegaly, short
stature, truncal obesity, a rounded doll face, hypothrophic muscles and
bleeding tendency due to impaired platelet function. The aim of dietary
treatment (frequent meals, nocturnal gastric drip feeding and oral
administration of uncooked cornstarch) is to prevent hypoglycaemia in order
to improve most biochemical and clinical abnormalities7.
In 1993 the G6Pase gene (G6PC) has been identified21,43. It is located in
band q21 of chromosome 17, consists of five exons, has a genomic length of
12.5 kb, and encodes a protein of 357 amino acids with a molecular mass of
35 kD. Using single strand conformation polymorphism (SSCP) analysis and
DNA sequencing, Lei et al22,23,24 characterised the G6Pase gene of 70 unrelated,
enzymatically confirmed, patients with GSD Ia. Sixteen different mutations
were identified. Twelve additional mutations were identified in a further 48
GSD Ia patients by other groups4,13,14,33.
We analysed the G6Pase gene of 16 GSD Ia patients and identified four
novel mutations.
Patients and methods
Mutation analysis of the G6Pase gene was performed in 16 unrelated
GSD Ia patients. All the patients shared the clinical as well as the biochemical
characteristics that are associated with GSD type Ia. Enzymological studies
were performed in fresh liver biopsy according to Narisawa et al29. In all GSD
Ia patients the activity of glucose-6-phosphate phosphohydrolase was
deficient or greatly reduced in both intact and disrupted liver microsomes.
Eight GSD Ia patients were of Dutch descent, five of German, two of Italian
and one of Moroccan descent. Where possible the G6Pase gene of the parents
was also analysed.
DNA was extracted from peripheral blood by the salting out method28.
The coding regions and intron/exon borders were amplified by polymerase
chain reaction (PCR) into six fragments (exon 5 into two overlapping
fragments) according to a modification of the method described by Lei et
al21,24. A new primer set for the exon 5-5' end was made to increase the
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length of the overlapping segment: GSD5-5’S: 5'-CTTCCTATCTCTCACAG-3'
(sense)21, and GSD5-5'A: 5'-TACAATAGAGCTGAGGC-3' (antisense;
nucleotides 963-979). The PCR amplified fragments were subjected to SSCP
analysis31 using two different conditions: (1) MDE nondenaturing gel (FMC
BioProducts), according to the manufacturer’s recommendations, and (2) 5
% polyacrylamide (PAA) gels containing 10 % glycerol. Both gels were run
at room temperature at 2000V/60W in 0.5*TBE buffer for 5 h. PCR-amplified
fragments showing an aberrant migration pattern were subjected to direct
sequencing by an automated sequencer (ALF, Pharmacia). Forward primers
were extended by an M13 oligonucleotide (CGACGTTG-TAAAACGACGGCCAGT)
to enable the use of an identical M13 sequence primer in all reactions, except
for the sequencing of the exon 5-5' fragment to which purpose the reverse
primer was extended.
Results and discussion
In all GSD Ia patients we were able to identify mutations on both alleles
by first using SSCP analysis prior to automated sequencing of exon(s)
revealing an aberrant SSCP pattern. These mutations are summarised in
Table 3.1.1.
The 100% detection rate indicates that the method used, is a reliable
procedure to identify mutations in the G6Pase gene. The approach is less
labour intensive compared to complete sequencing of the G6Pase coding
sequence. However, if no mutations are identified by SSCP analysis, all five
exons should be sequenced, since by relying on just SSCP analysis,
theoretically mutations might be missed.
Four novel mutations were identified: 175delGG, R170X, G266V and
V338F. 175delGG, identified in a compound heterozygous Dutch GSD Ia
patient (175delGG/Q347X), is a deletion of 2 bp at nucleotides 175 and 176
in exon 1, creating a frame shift, which leads to a direct stopcodon at position
59. The protein product is therefore, only 58 amino acid residues long and is
expected to be unstable at the cellular level. R170X, a nonsense mutation,
identified in a homozygous German patient (170X/170X) and in two compound
heterozygous unrelated Dutch patients (both 170X/F327del), is caused by a
C to T substitution at nucleotide 587 in exon 4, which generates a stopcodon
at position 170. The protein product is 169 amino acids long and is also
expected to be unstable at cellular level. G266V, a missense mutation,
identified in two compound heterozygous Dutch patients (158delC/G266V
and G266V/F327del), is caused by a G to T substitution at nucleotide 876 in
exon 5, leading to the substitution of a valine for a glycine at codon 266.
Although both glycine and valine are amino acids with aliphatic non-polar
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side chains, different arguments give reason to expect that G266V is a true
mutation and not a sequence variation with minor effects on the activity of
the gene product. One hundred and eight normal subjects were tested for
this missense mutation and on none of the 216 alleles this substitution was
found. Furthermore in mouse liver G6Pase, on the same position also a
glycine is found and the direct environment of this amino acid is conserved,
indicating that this part of the G6Pase protein is important for its functional
activity. Finally, the segregation of this mutation through both families was
as expected. Both mothers were heterozygous for G266V, whereas the other
mutation in both patients was of paternal origin. V338F, a missense mutation,
identified in a compound heterozygous Dutch GSD Ia patient (W63X/V338F),
is caused by a G to T substitution at nucleotide 1091 in exon 5, leading to
the substitution of a valine for a phenylalanine at codon 338. Valine is an
amino acid with an aliphatic non-polar side chain, whereas phenylalanine
contains an aromatic ring. Such a change could affect G6Pase activity or
stability. Considering this, as well as similar arguments as discussed for the
G266V mutation above, we conclude that V338F is a true mutation. The
SSCP analyses and the sequence analyses of the novel mutations are shown
in Figure 3.1.1 and Figure 3.1.2 respectively. The R170X, G266V and V338F
Table 3.1.1 Mutations in the G6Pase gene identified in 16 unrelated GSD Ia patients
allele 1 allele 2
descent exon nucleotide mutation exon nucleotide mutation father1 mother1
change change
I Dutch 2 326 CT R83C 5 1118 CT Q347X Q347X R83C
II Dutch 1 158delC 158delC 5 876 GT G266V 158delC G266V
III Dutch 1 268 GA W63X 5 1091 GT V338F W63X V338F
IV Dutch 5 876 GT G266V 5 1058delTTC F327del F327del G266V
V Moroccan 2 326 CT R83C 2 326 CT R83C R83C R83C
VI Dutch 4 587 CT R170X 5 1058delTTC F327del n.a. n.a.
VII German 4 587 CT R170X 4 587 CT R170X n.a. n.a.
VIII German 2 327 GA R83H 2 327 GA R83H R83H n.a.
IX Dutch 1 158delC 158delC 1 158delC 158delC n.a. n.a.
X German 2 326 CT R83C 5 1118 CT Q347X n.a. Q347X
XI Dutch 4 587 CT R170X 5 1058delTTC F327del R170X F327del
XII Dutch 1 175delGG 175delGG 5 1118 CT Q347X n.a. n.a.
XIII Italian 2 326 CT R83C 2 326 CT R83C R83C R83C
XIV German 4 641 GC G188R2 5 1118 CT Q347X n.a. n.a.
XV Italian 2 326 CT R83C 2 326 CT R83C R83C R83C
XVI German 5 888 GT G270V 5 1118 CT Q347X Q347X G270V
The novel mutations identified in this study are in bold face.
n.a. not available.
1 Mutations identified on one of both alleles of the G6Pase gene of the parents. All parents
were non-consanguineous, except for the parents of patient V
2 Besides leading to an amino acid change, this mutation disturbs most likely also the




mutations can also be detected by restriction analysis of the amplification
product of the exon in which they are contained; they create Nla III, Bsp1286I
and Eco57I sites respectively.
In both patients of Italian descent and in the patient of Moroccan descent,
R83C (6/6) was homozygously present. In the 13 Dutch and German GSD Ia
patients, 12 different mutations were identified. Most frequently Q347X was
found (5/26). Eleven additional mutations account for the remaining 21
mutant alleles. This allelic heterogeneity in Caucasian patients and allelic
homogeneity in patients from a more specifically defined ethnical and/or
geographical origin, is in agreement with previous reports by other groups.
In Caucasian patients from the USA and France most frequently Q347X (31%)
and R83C (27%) were found, but 20 additional mutations account for the
other mutant alleles. On the other hand in Jewish patients (R83C, 93%),
Mediterranean patients (R83C, 71%; Q347X, 29%), Hispanic patients
(459insTA, 50%; R83C, 28%), Chinese patients from the USA (R83H, 70%)
and Japanese patients (727 T→G, 94%) one or two predominantly occurring
mutations were found4,14,24,33. This opens the way to test for specific G6Pase
gene mutations prior to a complete SSCP analysis in these patients.
Figure 3.1.1  SSCP analyses of the four novel G6Pase mutations
lane 1 wild type SSCP pattern
lane 2 heterozygous mutant SSCP pattern
(a) exon 1, 175delGG
(b) exon 4, R170X
(c) exon 5-5’, G266V
(d) exon 5-3’, V338F
The exon-containing fragments were amplified by PCR and were analysed by
electrophoresis on MDE gels (a,c,d) or 5% PAA gel containing 10% glycerol (b)
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Figure 3.1.2  Sequence analyses of the four novel G6pase mutations
Detection of the (a) 175delGG; (b) R170X; (c) G266V; (d) V338F mutations by direct
sequencing of exon-containing PCR products. Normal and mutant sequences are shown.
The position of the mutations is indicated by an arrow. Heterozygous nucleotides are
indicated by a letter code: K means G and T; S means G and C;
M means A and C; B means C, G and T; W means A and T; Y means C and T
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Characterisation of the human G6Pase gene and defining the mutational
spectrum of this gene allows a DNA-based diagnosis in patients clinically
suspected of having GSD Ia. However, if no alterations in the G6Pase gene
can be identified, enzyme assays with specific substrates in intact and
disrupted microsomes obtained by liver biopsy remain necessary.
Furthermore, once mutations are identified in a family at risk for having an
offspring with GSD Ia, prenatal DNA-based diagnosis in chorionic villus
samples is possible20,34,38.
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3.2 Identification of a novel mutation (867delA) in the
glucose-6-phosphatase gene in two siblings with
Glycogen Storage Disease type Ia with different
phenotypes.
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We identified a novel mutation (867delA) in the glucose-6-phosphatase
gene of two siblings with glycogen storage disease type Ia. Although both
siblings share the same mutations, their phenotype regarding adult height
and hepatomegaly differs. In glycogen storage disease type Ia, substantial
heterogeneity in genotype and phenotype is observed. At present, no evidence
for a clear genotype-phenotype correlation has been found.
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Introduction
Glycogen storage disease type Ia (GSD Ia, MIM# 232200) is a severe
autosomal recessive inborn error of metabolism caused by microsomal
glucose-6-phosphatase (G6Pase, E.C.3.1.3.9) deficiency. The disease
phenotype is characterised by marked hepatomegaly, short stature, severe
fasting hypoglycaemia, hyperlactacidaemia, hyperuricaemia and hyper-
lipidaemia. Life expectancy in GSD I has improved considerably, thanks to
intensive dietary therapy including frequent meals, slowly released
carbohydrates and continuous nocturnal gastric drip feeding. However, with
ageing, numerous complications, such as liver adenomas, progressive renal
disease, and osteopenia may develop7.
After identification of the gene encoding the G6Pase catalytic unit (G6PC;
GDB 231927)21, a steadily growing list of mutations has been reported. In
addition to our previous work39, we report here a novel mutation in the
G6Pase gene, identified in two siblings with different phenotypes.
Patients and methods
The affected index cases are a 24-year-old brother (sibling 1) and a 20-
year-old sister (sibling 2), progeny of unrelated healthy Dutch Caucasian
parents. In sibling 1 the diagnosis GSD Ia was suspected at the age of six
months, in sibling 2 shortly after birth. Enzyme assays in liver tissue obtained
by biopsy revealed 10% residual G6Pase activity in sibling 1 and no residual
G6Pase activity in sibling 2. From early infancy both patients had been treated
with frequent lactose-restricted feedings during day and night. At four years
of age and one year of age respectively, continuous gastric drip feeding was
introduced. At twelve years of age and eight years of age respectively,
uncooked cornstarch during the day was introduced. The patients are raised
in a family in which dietary treatment was maintained stringently for both.
At present, both patients are in good clinical condition. They share some
of the disease phenotype characteristics: mild hypercholesterolemia,
hypertriglyceridemia and hyperuricemia requiring a xanthine-oxidase inhibitor.
Furthermore, both patients have renal hyperfiltration and microalbuminuria
requiring an angiotensin converting enzyme inhibitor. Liver adenomas could
not be detected in either sibling. Bone mineral density is reduced in both.
However, the clinical phenotype regarding adult height and hepatomegaly
differs. Sibling 1 has reached an adult height of 195.4 cm (+ 2.0 SDS),
sibling 2 of 166.0 cm (- 0.4 SDS). In sibling 1, hepatomegaly (liver 2 cm
palpable below costal margin in medioclavicular line) is less pronounced
compared with sibling 2 (liver 9 cm).
 Genomic DNA preparations, PCR amplification, single-stranded
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conformation polymorphism (SSCP) and sequence analysis were performed
as described earlier39.
Results and discussion
In both siblings, SSCP analyses of exon 1 and exon 5-5’revealed aberrant
migration patterns. Subsequent sequencing of the PCR-amplified exon 1
fragment revealed a known frameshift mutation, 175delGG38. Sequencing of
the PCR-amplified exon 5-5’fragment revealed a deletion of an adenine at
nucleotide 867 (867delA) resulting in a stopcodon at position 300. This
frameshift mutation has not been described before. Although no transient
expression analyses have been performed, most likely both mutations lead
to protein products with completely abolished G6Pase activity. Lei et al25
showed that only the 8 carboxyl-terminal amino acids (350-357) in human
G6Pase are not essential for G6Pase activity or membrane retention. A
stopcodon preceding these 8 residues causes loss of catalytic activity of
G6Pase.
Both siblings share the same mutations in the G6pase gene. However,
their phenotype regarding residual activity of G6Pase in liver tissue, adult
height, and hepatomegaly differs. The difference in residual enzyme activity
could reflect differences in quality of liver tissue (fat and glycogen storage
displace normal liver tissue), differences in biopsy localisation (hepatic
zonation of G6Pase activity) or analytical considerations (enzyme assays
were performed in different laboratories). However, the in vitro observed
variability could also reflect real difference in enzyme activity. The difference
in phenotype regarding adult height and hepatomegaly could reflect this
difference in residual enzyme activity, but also hepatic glycogen breakdown
or glucose production by alternative pathways may play a role. Furthermore,
it is possible that other modifying genes may be involved.
Since substantial heterogeneity in phenotype in GSD Ia is observed, a
genotype-phenotype correlation may be very helpful to adjust dietary and
pharmacological strategies. However, no evidence for a clear genotype-
phenotype correlation has been found so far. Even of the presented siblings
who share the same mutations in the G6Pase gene, phenotypes differ.
In summary, we identified a novel mutation (867delA) in the glucose-6-
phosphatase gene of two siblings with glycogen storage disease type Ia. In
glycogen storage disease type Ia, substantial heterogeneity in genotype and
phenotype is observed. However, at present no evidence for a clear genotype-
phenotype correlation has been found.
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3.3 Glycogen Storage Disease type Ia: recent
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We studied the glucose-6-phosphatase (G6Pase) gene of 30 unrelated
glycogen storage disease type Ia (GSD Ia) patients using single strand
conformational polymorphism (SSCP) prior to automated sequencing of exons
revealing an aberrant SSCP pattern. In all patients we could identify mutations
on both alleles of the G6Pase gene, indicating that this method is a reliable
procedure. A total of 14 different mutations were identified. R83C (16/60),
158delC (12/60), Q347X (7/60), R170X (6/60) and ∆F327 (4/60) were found
most frequently. Nine other mutations account for the other 15 mutant alleles.
Two DNA-based prenatal analyses were performed successfully. At present,
56 mutations in G6Pase gene have been reported in 300 unrelated GSD Ia
patients and an overview of these mutations is presented. Evidence for a
clear genotype-phenotype correlation could be established neither from our
data, nor from those in the literature. With increased knowledge about the
genetic basis of GSD Ia and GSD Ib and the high detection rate of mutations,
it is our opinion that the diagnoses GSD Ia and GSD Ib can usually be based
on clinical and biochemical abnormalities combined with mutation analysis
instead of enzyme assays in liver tissue obtained by biopsy. A newly developed
flowchart for the diagnosis of GSD I is presented.
In conclusion, increased knowledge of the genetic basis of GSD I provides
a DNA-based diagnosis, prenatal DNA-based diagnosis in chorionic villus
samples and carrier detection.
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Introduction
Glucose-6-phosphatase (G6Pase, E.C.3.1.3.9) is the key enzyme in the
regulation of blood glucose homeostasis by catalysing the terminal step in
both glycogenolysis and gluconeogenesis. Deficient G6Pase activity leads to
glycogen storage disease type I (GSD I, McKusick 232200), an autosomal
recessive inborn error of metabolism, which has a frequency among newborns
of one in 100.000 to 1 in 300.0003. Based on the most plausible model,
G6Pase is a multi component enzyme complex consisting of a catalytic subunit,
with one or more membrane transporters. The catalytic subunit is situated
on the luminal surface of the endoplasmic reticulum to which substrates
gain access by the transporters. Based on kinetic studies in liver tissue four
different subtypes of GSD I could be distinguished: GSD Ia which is caused
by deficient activity of the catalytic unit, and GSD Ib, GSD Ic and GSD Id
which are caused by defects of glucose-6-phosphate (G6P) translocase,
phosphate/pyrophosphate translocase and a putative glucose translocase,
respectively51.
In 1993 the gene encoding the G6Pase catalytic unit was identified21,43. It
is located in band q21 of chromosome 17, consists of five exons, has a
genomic length of 12.5 kb and encodes a protein of 357 amino acids with a
molecular mass of 35 kD. A steadily growing number of mutations in the
G6Pase gene has been reported. More recently also the gene encoding the
G6P transporter was identified1,9. It is located in band q23 of chromosome
11 and consists of nine exons. In GSD Ib and GSD Ic patients and in a GSD
Id patient, allelic mutations have been identified, indicating that for those
subtypes the basic defect is in the putative G6P translocase and that they
should be reclassified as GSD Ib49.
Following our previous reports about mutation analysis in GSD Ia
patients39,40, we report here the results of mutation analysis in 30 GSD Ia
patients, including two DNA-based prenatal analyses. Furthermore, we present
an overview of the mutations in the G6Pase gene reported in literature so
far. Finally, we present a newly developed flowchart for the diagnosis of GSD
Ia and GSD Ib.
Patients and methods
DNA analyses of the G6Pase gene in 30 GSD type Ia patients and their
families was carried out. In patients 1 to 21, the clinical diagnosis GSD Ia
had already confirmed by enzyme assay in biopsied liver tissue according to
Narisawa et al29. In these patients, mutation analysis was performed to confirm
the diagnosis at the molecular level. In patients 22 to 30, the diagnosis GSD
Ia was suspected on the basis of both clinical and biochemical characteristics.
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In these patients mutation analysis was performed to establish the diagnosis.
In addition, in the families of patients 12 and 20, DNA-based prenatal diagnosis
in chorionic villus samples (CVS) was performed. Furthermore, in the partners
of patient 1 and 4, DNA analysis was performed to reduce the likelihood of
being a carrier of a mutant G6Pase allele. In a newborn sibling of patient 25,
postnatal mutation analysis was performed to exclude GSD Ia.
Genomic DNA was extracted from leukocytes from peripheral blood or
from CVS obtained by transcervical biopsy in the first trimester of gestation.
DNA was extracted from leukocytes by the salting out method28 and from
CVS by phenol/chloroform extraction. The coding regions and intron/exon
borders were amplified by PCR into six fragments (exon 5 in two overlapping
fragments) according to a modification of the method described by Lei et
al21,24. A new  primer set for the exon 5-5' end was designed to increase the
length of the overlapping segment: GSD5-5’S: 5'-CTTCCTATCTCTCACAG-3'
(forward)21, and GSD5-5'A: 5'-TACAATAGAGCTGAGGC-3' (reverse: nucleotides
963-979). The PCR amplified fragments were subjected to single strand
conformational polymorphism (SSCP) analysis31 using two different conditions:
(1) MDE nondenaturing gel (FMC BioProducts), according to the
manufacturer’s recommendations, and (2) 5% polyacrylamide (PAA) gels
containing 10% glycerol. Both gels were run at room temperature at 2000V/
60W in 0.5*TBE buffer for 5h. PCR-amplified fragments showing an aberrant
migration pattern were subjected to direct sequencing by an automated
sequencer (ALF, Pharmacia). Forward primers were extended by an M13
oligonucleotide (CGACGTTGTAAAACGACGGCCAGT) to enable the use of an
identical M13 sequence primer in all reactions, except for the sequencing of
the exon 5-5' fragment for which purpose the reverse primer was extended.
Results
In all 30 GSD Ia patients we were able to identify mutations on both
alleles of the G6Pase gene (Table 3.3.1) providing a total of 14 different
mutations.
Mutation analysis performed in the newborn sibling of patient 25 indicated
that he had received at least one normal G6Pase allele, excluding GSD Ia.
Subsequently, he developed no suspect clinical features.
Mutation analysis of DNA extracted from CVS in families of patients 12
and 20 indicated that both fetuses received at least one normal G6Pase
allele. Both pregnancies were carried to term and healthy babies were born.
In the partners of patient 1 and 4 no aberrant SSCP patterns were detected.
Discussion
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Table 3.3.1  Mutations in the G6Pase gene identified in 30 unrelated GSD Ia patients and
their families (n.a. not available; conf diagnosis based on enzyme assays and confirmation
by mutation analysis; DNA diagnosis based on mutation analysis; cvs DNA-based prenatal
diagnosis in CVS; c.det carrier detection)
          allele 1        allele2
descent nucleotide mutation nucleotide mutation fathera mothera
change change
1 conf Dutch 2 326C→T R83C 5 1118C→T Q347X Q347X R83C
2 conf/c.detb Dutch 1 158delC 158delC 5 876G→T G266V 158delC G266V
3 conf/c.detb Dutch 1 268G→A W63X 5 1091G→T V338F W63X V338F
4 conf Dutch 5 876G→T G266V 5 1058delTTC F327del F327del G266V
5 conf/DNAc Moroccan 2 326C→T R83C 2 326C→T R83C R83C R83C
6 conf Dutch 4 587C→T R170X 5 1058delTTC F327del n.a. n.a.
7 conf German 4 587C→T R170X 4 587C→T R170X n.a. n.a.
8 conf German 2 327G→A R83H 2 327G→A R83H R83H n.a.
9 conf Dutch 1 158del C 158delC 1 158del C 158delC n.a. n.a.
10 conf German 2 326C→T R83C 5 1118C→T Q347X n.a. Q347X
11 conf Dutch 4 587C→T R170X 5 1058delTTC F327del R170X F327del
12 conf/cvse Dutch 1 175delGG 175delGG 5 1118C→T Q347X n.a. n.a.
13 conf Italian 2 326C→T R83C 2 326C→T R83C R83C R83C
14 conf German 4 641G→C G188Rd 5 1118C→T Q347X n.a. n.a.
15 conf Italian 2 326C→T R83C 2 326C→T R83C R83C R83C
16 conf German 5 888G→T G270V 5 1118C→T Q347X Q347X G270V
17 conf Dutch 1 175delGG 175delGG 5 867delA 867delA n.a. n.a
18 conf Dutch 1 158delC 158delC 5 1118C→T Q347X n.a. n.a.
19 conf Dutch 1 158delC 158delC 1 158del C 158delC n.a. n.a.
20 conf/cvse Belgium 1 158delC 158delC 1 158delC 158delC 158delC 158delC
21 DNA Dutch 2 326C→T R83C 2 326C→T R83C n.a. n.a.
22 DNA Dutch 1 158delC 158delC 5 867delA 867delA 158delC 867delA
23 DNA German 2 326C→T R83C 2 326C→T R83C n.a. n.a.
24 DNA Dutch 4 587C→T R170X 5 1058delTTC F327del F327del R170X
25 DNAf British 1 268G→A W63X 5 1118 C→T Q347X W63X Q347X
26 DNA Austria 2 326C→T R83C 2 326C→T R83C R83C R83C
27 DNA Austria 1 158delC 158delC 4 588G→A R170Q R170Q 158delC
28 DNA Belgium 1 158delC 158delC 1 158delC 158delC 158delC 158delC
29 DNA Belgium 1 268G→A W63X 4 587C→T R170X n.a. n.a.
30 DNA Dutch 2 326C→T R83C 2 326C→T R83C n.a. n.a.
a Mutations identified on one of both alleles of the G6Pase gene of the parents: all parents
were nonconsanguineous, except for the parents of patient 5 (third degree nephew-
niece)
b No aberrant SSCP pattern could be detected in the partners of both patients
c Index patient diagnosed by enzyme assays and confirmed by mutation analysis. Next
patient (father is a brother and mother is a third degree niece of index patient) diagnosed
by mutation analysis
d Besides leading to an amino acid change, this mutation disturbs most likely also the
correct splicing of the G6Pase mRNA, as it located at the last nucleotide of exon 4
4
e Index patients diagnosed by enzyme assays and confirmed by mutation analysis. During
next pregnancies DNA-based prenatal diagnosis: both fetuses received at least one
normal G6Pase allele.
f Index patient diagnosed by mutation analysis. In newborn sibling DNA analysis to exclude

















We analysed the G6Pase gene of 30 unrelated GSD Ia patients. In all
patients both mutations of the G6Pase gene were identified. The DNA analysis
in patients 1 to 17 have been reported previously39,40. The mutations R83C
(16 of the 60 alleles), 158delC (12/60), Q347X (7/60), R170X (6/60) and
∆F327 (4/60) were found most frequently. Nine other mutations account for
the other 15 mutant alleles.
At present, 56 mutations in the G6Pase gene have been reported in 300
(600 alleles) unrelated GSD Ia patients4,5,12-19,21-24,26,27,30,33,35-37,39-41,44-46,this study.
An overview of these mutations is given in Table 3.3.2. Among the 56
mutations, 11 are frameshift mutations, three are splice site mutations, seven
are nonsense mutations, 34 are missense mutations and one is a codon
deletion mutation. The frameshift mutations result in codons for different
amino acids at the 3' side of the mutation. Eight of these eleven frameshift
mutations, 97insTGAA, 158delC, 175delGG, 341delG, 459insTA, 518delA/
518insTG, 813insC and 867delA create a stopcodon at positions 11, 35, 59,
101, 130, 203, 254 and 300, respectively. The other three, 79delC,
540delTTTTG and 813insG-822delC, do not create a premature stopcodon.
Transient expression analyses of 459insTA and 813insG-822delC have shown
abolished G6Pase activity23,24. It can be expected however, that all these
frameshift mutations lead to protein products with abolished G6Pase activity
since only the 8 carboxyl-terminal amino acids (350-357) in human G6Pase
are not essential for G6Pase activity or membrane retention25. Three splice
site mutations have been identified. 309+4 A→G results in the retainment
of intron 1 in the mRNA4. 727G→T is thought to be the cause of a defective
splicing of intron 4, resulting in a 91 nucleotide deletion of exon 5 and altering
the reading frame resulting in a stopcodon at position 21214. Matsubara et
al27 identified in intron 1 a not further specified altered consensus splice
acceptor site sequence, causing exon 2 skipping in ectopic mRNA. Seven
nonsense mutations, W50X, W63X, W70X, R170X, Y172X, Q242X and Q347X,
in which a single DNA base change results in a premature stopcodon, have
been identified. These mutations lead to truncated protein products which
all can be expected to be unstable. Transient expression analyses have shown
this for W63X, Q242X and Q347X22,24. A total of 34 missense mutations, 33
in which a single DNA base change and one (L345R) in which two subsequent
DNA base changes result in nucleotide triplets coding for different amino
acids, have been identified. Among those missense mutations, G188S and
G188R most likely also disturb the correct splicing of the G6Pase mRNA
because these mutations are positioned at the last nucleotide of exon 44.
Furthermore, one codon deletion mutation, in which deletion of three
subsequent DNA bases results in the deletion of an amino acid (∆F327), has
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been identified. Transient expression analyses of D38V, R83C, R83H, V166G,
P178S, G188S, G270V, R295C, ∆F327 and L345R have shown abolished
G6Pase activity, whereas transient expression analyses of E110Q, G222R,
W236R have shown greatly reduced G6Pase activity21,23,24,35,36. So far, no
transient expression assays have been performed for the other 22 missense
mutations (Q20R, W63R, G68R, W77R, G81R, E110Q, E110K, P113L, A124T,
V166A, R170Q, Y172X, G184E, G184V, G188R, L211P, P257L, L265P, G266V,
S298P, V338F, I341N) but different arguments give reason to expect that
these are true mutations and not sequence variations with no or only minor
effects on the activity of the gene protein product. In large groups of normal
subjects, who were tested for these missense mutations, these substitutions
could not be identified in any of the alleles. Furthermore, normal sequence
polymorphisms in the coding sequences of the G6Pase gene could not be
identified by testing 180 G6Pase alleles24. Also the segregation of the different
missense mutations through the families was as expected.
Recently, it was demonstrated that the topology of human G6Pase is
rather a nine-transmembrane helical structure with the N-terminus and four
loops localized on the luminal side of the endoplasmatic reticulum, than a
six-transmembrane helical structure as was suggested previously11,32.
According to the nine-transmembrane helical topology, 25 missense mutations
and the codon deletion mutation result in amino acid changes in one of the
transmembrane spanning segments, indicating the importance of the
structural integrity of those segments. The other nine missense mutations
result in amino acid changes in the N-terminal domain (one mutation), loop
1L (five mutations in three different codons), loop 2L (one) and loop 3L (two
in two), all located on the luminal side of the endoplasmic reticulum. Till so
far no mutations have been identified in loop 4L and the four cytoplasmic
loops, suggesting that those loops are less important for phosphohydrolase
activity of G6Pase.
Among the 56 different mutations identified in 600 alleles of 300 unrelated
GSD Ia patients, the two missense mutations R83C and Q347X and the
splice site mutation 727G→T account for more than 60% of all mutant G6Pase
alleles (32.5%, 14.3% and 11.3% respectively). No other mutation account
for almost 5%; 28 mutations are even ‘private’ or single allele mutations. An
overview of the prevalence of the different mutations among different
geographical/ethnical groups is given in Table 3.3.2. Striking is the allelic
heterogeneity in Caucasian patients from the USA and from North-West Europe
and the allelic homogeneity in patients of some specifically defined ethnic
and/or geographical origin. In Caucasian patients from the USA and North-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































alleles respectively, but 34 additional mutations have already been identified.
On the other hand, in Jewish patients (R83C, 93%), Chinese patients from
the USA (R83H, 70%), Hispanic patients (459insTA, 50% and R83C, 28%),
Japanese patients (727G→T, 88%), patients from South-Europe (R83C, 48%
and Q347X, 21%) and Turkish patients (R83C, 60%), one or two
predominantly occurring mutations are found. This opens the way to test for
specific G6Pase gene mutations in patients with these background prior to a
complete analysis.
We were able to identify mutations in the G6Pase gene on both alleles of
all patients by using SSCP prior to automated sequencing of the exons
revealing an aberrant SSCP pattern. This indicates that this method is a
reliable procedure to identify mutations in the G6Pase gene. The high detection
rate of mutations in the G6Pase gene is in line with published data (an
overall detection rate of 87.8%). Because of this high detection rate, we feel
that this approach is also adequate for carrier detection in partners of a
known G6Pase mutation carrier. We analysed the G6Pase gene of the partners
of patient 1 and 4 and found no aberrant SSCP patterns; however one should
keep in mind that with SSCP analysis, mutations in the 5’UTR and 3’UTR and
mutations in the control regions of the G6Pase gene will not be identified.
Identification of mutations on both G6Pase alleles of a GSD Ia index-case
allows reliable prenatal DNA-based diagnosis in CVS by restriction enzyme
analysis38,47, sequencing20 or SSCP analysis34. We successfully performed
prenatal DNA-based diagnosis in families 12 and 20 by direct sequencing.
With increased knowledge of the genetic basis of GSD I and the high
detection rate of mutations in the G6Pase and G6P translocase genes, it is
our opinion that the diagnoses GSD Ia and GSD Ib can be based on clinical
and biochemical abnormalities combined with mutation analysis instead of
enzyme assays in liver tissue obtained by biopsy. Marked hepatomegaly,
severe fasting hypoglycaemia and hyperlactacidaemia are the most striking
abnormalities in GSD I. Other abnormalities are stunted growth, a rounded
doll face, truncal obesity, hypothrophic muscles, diarrhoea, hyperlipidaemia,
hyperuricaemia and bleeding tendency due to impaired platelet function7.
Patients with GSD Ib may suffer from recurrent bacterial infections and
inflammatory bowel disease in addition, due to neutropenia and neutrophil
dysfunction10. A diagnostic flowchart to the diagnosis of GSD Ia and GSD Ib
is presented in Figure 3.3.1. If patients suffer from neutropenia or neutrophil
dysfunction, mutations in the G6P translocase gene should be excluded first.
However, one should keep in mind that especially in younger GSD Ib patients,
these specific features are not obligatory50. If two mutations in the G6Pase
gene or in the G6P translocase gene are identified, enzyme assays in liver
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tissue obtained by biopsy are not necessary to establish the diagnosis GSD
Ia or GSD Ib. If mutations neither in the G6Pase gene nor in the G6P
translocase gene are identified, a glucose tolerance test should be performed.
A marked decrease of blood lactate concentration from an elevated level at
zero time is observed in patients with GSD I. This pattern is also observed in
(other) disorders of gluconeogenesis. An increase of blood lactate
concentration is observed in other glycogen storage diseases8. If the suspicion
of GSD I remains, enzyme assays in liver tissue should be performed. These
assays can be simplified however, because it is only necessary to measure
G6Pase activity in intact and disrupted liver microsomes to establish the
diagnosis GSD Ia or GSD Ib49. DNA-based diagnosis requires two mutations.
Consequently, the diagnosis GSD Ia or GSD Ib may not be established officially
if only one mutation in the G6Pase gene or in the G6P translocase gene is
identified. However, with one mutation in the G6Pase gene or in the G6P
translocase gene, the likelihood of having a different disease resembling
GSD Ia or GSD Ib is virtually zero. Therefore, one should discuss for each
individual patient with only one mutation identified whether a liver biopsy is
needed to establish the definite diagnosis. For DNA-based prenatal diagnosis
in the mother’s possible next pregnancy, identification of the second mutation




 As a large heterogeneity in phenotype in GSD Ia is observed, a genotype-
phenotype correlation may be very helpful to adjust dietary and pharma-
cological strategies6. However, evidence for a clear genotype-phenotype
correlation could be established neither from our data, nor from data in the
literature.
In conclusion, using SSCP prior to automated sequencing of the exons
revealing an aberrant pattern, we were able to identify mutations in the
G6Pase gene on both alleles of all 30 GSD Ia patients we studied. The
increased knowledge of the genetic basis of GSD Ia and GSD Ib allows DNA-
based diagnosis instead of enzyme assays in liver tissue obtained by biopsy.
Furthermore, it allows prenatal DNA-based diagnosis in CVS and carrier
detection.
Addendum
In the period between acceptance and publication of this manuscript,
three more molecular genetic studies concerning GSD Ia were published2,42,48.
Bruni et al 2 reported that transient expression analyses of four previous
identified missense mutations, W77R, A124T, G184E and L211P, showed
totally abolished G6Pase activity. Seydewitz et al42 reported five novel
mutations: Q20R (A138G), W50X (G228A) and G81R (G320A) were
mentioned earlier in an appendix to a study of the same group26; W156L
(G546T), a missense mutation in exon 4, and G188D (G642A), a missense
mutation in exon 5 and most likely also disturbing the correct splicing of the
G6Pase mRNA, were not reported previously. Finally, Trioche et al48 reported
3 novel mutations: Q54P (A240C), a missense mutation in exon 1, W70X
(G288A), a nonsense mutation in exon 1 and previously reported26, and
T108I (C402T), a missense mutation in exon 2.
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